Front Row Advisors LLC Bei Gene, Ltd. Transaction History

Front Row Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$129.52 - $174.32 $129 - $174	-1 Reduced 5.26%	18 $2,000
Q1 2024 May 14, 2024	BUY	$141.8 - $181.47 $2,694 - $3,447	19 New	19 $2,000
Q3 2023 Nov 15, 2023	SELL	$179.87 - $225.13 $539 - $675	-3 Reduced 25.0%	9 $1,000
Q1 2023 May 22, 2023	BUY	$215.53 - $274.5 $1,939 - $2,470	9 Added 300.0%	12 $3,000
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $2,155 - $2,745	-10 Reduced 76.92%	3 $1,000
Q4 2022 Feb 15, 2023	SELL	$125.51 - $229.3 $251 - $458	-2 Reduced 13.33%	13 $3,000
Q3 2022 Nov 15, 2022	SELL	$131.8 - $202.24 $263 - $404	-2 Reduced 11.76%	15 $2,000
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $363 - $648	-3 Reduced 15.0%	17 $3,000
Q3 2021 Nov 03, 2021	SELL	$249.6 - $403.14 $748 - $1,209	-3 Reduced 13.04%	20 $7,000
Q2 2021 Aug 23, 2021	BUY	$292.75 - $367.01 $1,171 - $1,468	4 Added 21.05%	23 $6,000
Q4 2020 Feb 25, 2021	SELL	$221.31 - $316.61 $221 - $316	-1 Reduced 5.0%	19 $5,000
Q3 2020 Nov 30, 2020	BUY	$189.18 - $286.44 $3,783 - $5,728	20 New	20 $6,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.